Using gene testing to guide treatment for drug-resistant tuberculosis
Part of Immune system & allergy, Infections clinical trials.
This study uses next-generation gene testing to help manage active drug-resistant tuberculosis. It may help doctors choose the most appropriate treatment by better identifying the TB’s drug resistance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active drug-resistant TB (RR-TB) diagnosed at the study site during the study time period
- Your TB sample tests positive (by culture, smear, or a related lab test) at the study facility
- You plan to stay living in the study area for the study period
- You agree to take part in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if measuring the amount of linezolid medicine in your blood helps treat rifampin-resistant tuberculosis more safely and effectively. It is for people who have already started a treatment plan that includes linezolid.
This study tests whether using a detailed sputum test to guide treatment for drug-resistant tuberculosis (TB) leads to better outcomes. Participants' treatment is tailored based on the specific drug resistance found, which may help them recover faster and reduce side effects.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This study tests rapid TB screening and lab-style diagnostic methods to see how well they find TB disease and TB that is resistant to rifampin (a key TB drug). It may help doctors diagnose TB faster and more accurately, especially in people at higher risk.
This study looks at whether TB bacteria are resistant to the drugs used for treatment. It helps doctors understand which medicines work best for newly diagnosed patients.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
Hear when a new Drug-resistant Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.